

\$%^STN;HighlightOn= \*\*\*;HighlightOff=\*\*\* ;

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
 NEWS 2 AUG 15 CAOLD to be discontinued on December 31, 2008  
 NEWS 3 OCT 07 EPFULL enhanced with full implementation of EPC2000  
 NEWS 4 OCT 07 Multiple databases enhanced for more flexible patent  
 number searching  
 NEWS 5 OCT 22 Current-awareness alert (SDI) setup and editing  
 enhanced  
 NEWS 6 OCT 22 WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT  
 Applications  
 NEWS 7 OCT 24 CHEMLIST enhanced with intermediate list of  
 pre-registered REACH substances  
 NEWS 8 NOV 21 CAS patent coverage to include exemplified prophetic  
 substances identified in English-, French-, German-,  
 and Japanese-language basic patents from 2004-present  
 NEWS 9 NOV 26 MARPAT enhanced with FSORT command  
 NEWS 10 NOV 26 MEDLINE year-end processing temporarily halts  
 availability of new fully-indexed citations  
 NEWS 11 NOV 26 CHEMSAFE now available on STN Easy  
 NEWS 12 NOV 26 Two new SET commands increase convenience of STN  
 searching  
 NEWS 13 DEC 01 ChemPort single article sales feature unavailable  
 NEWS 14 DEC 12 GBFULL now offers single source for full-text  
 coverage of complete UK patent families  
 NEWS 15 DEC 17 Fifty-one pharmaceutical ingredients added to PS  
 NEWS 16 JAN 06 The retention policy for unread STNmail messages  
 will change in 2009 for STN-Columbus and STN-Tokyo  
 NEWS 17 JAN 07 WPIDS, WPINDEX, and WPIX enhanced Japanese Patent  
 Classification Data

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,  
 AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that  
 specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 08:24:31 ON 13 JAN 2009

```
=> ENTER REGISTRY
COST IN U.S. DOLLARS          SINCE FILE   TOTAL
                               ENTRY   SESSION
FULL ESTIMATED COST          0.22    0.22
```

FILE 'REGISTRY' ENTERED AT 08:24:53 ON 13 JAN 2009  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 11 JAN 2009 HIGHEST RN 1093181-04-4  
 DICTIONARY FILE UPDATES: 11 JAN 2009 HIGHEST RN 1093181-04-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
 predicted properties as well as tags indicating availability of  
 experimental property data in the original document. For information  
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

```
=> S tcgtcgttttttcggtcgtttt/SQEN
    20 TCGTCGTTTTTCGGTCGTTTT/SQEN
    484263 SQL=21
L1   20 TCGTCGTTTTTCGGTCGTTTT/SQEN
      (TCGTCGTTTTTCGGTCGTTTT/SQEN AND SQL=21)
```

```
=> D SEC NTE LC 20
'SEC' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'
```

The following are valid formats:

Substance information can be displayed by requesting individual  
 fields or predefined formats. The predefined substance formats  
 are: (RN = CAS Registry Number)

REG -- RN  
 SAM -- Index Name, MF, and structure - no RN  
 FIDE -- All substance data, except sequence data  
 IDE -- FIDE, but only 50 names  
 SQIDE -- IDE, plus sequence data  
 SQIDE3 -- Same as SQIDE, but 3-letter amino acid codes are used  
 SQD -- Protein sequence data, includes RN  
 SQD3 -- Same as SQD, but 3-letter amino acid codes are used  
 SQN -- Protein sequence name information, includes RN

EPROP -- Table of experimental properties  
 PPROP -- Table of predicted properties  
 PROP -- EPROP, ETAG, PPROP and SPEC

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract  
 APPS -- Application and Priority Information  
 BIB -- CA Accession Number, plus Bibliographic Data  
 CAN -- CA Accession Number  
 CBIB -- CA Accession Number, plus Bibliographic Data (compressed)  
 IND -- Index Data  
 IPC -- International Patent Classification  
 PATS -- PI, SO  
 STD -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels  
 IBIB -- BIB, indented, with text labels  
 ISTD -- STD format, indented

OBIB ----- AN, plus Bibliographic Data (original)  
 OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations  
 SIBIB ----- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.

The MAX format is the same as ALL.

The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDs -- To see a complete list of individual display fields.  
 HELP FORMATS -- To see detailed descriptions of the predefined formats.  
 ENTER DISPLAY FORMAT (IDE):  
 ENTER DISPLAY FORMAT (IDE):D SEQ NTE LC 20  
 'D' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

REG - RN  
 SAM - Index Name, MF, and structure - no RN  
 FIDE - All substance data, except sequence data  
 IDE - FIDE, but only 50 names  
 SQIDE - IDE, plus sequence data  
 SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used  
 SQD - Protein sequence data, includes RN  
 SQD3 - Same as SQD, but 3-letter amino acid codes are used  
 SQN - Protein sequence name information, includes RN

EPROP - Table of experimental properties  
 PPROP - Table of predicted properties  
 PROP - EPROP, ETAG, PPROP and SPEC

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract  
 APPS -- Application and Priority Information  
 BIB -- CA Accession Number, plus Bibliographic Data  
 CAN -- CA Accession Number  
 CBIB -- CA Accession Number, plus Bibliographic Data (compressed)  
 IND -- Index Data  
 IPC -- International Patent Classification  
 PATS -- PI, SO  
 STD -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels  
 IBIB -- BIB, indented, with text labels  
 ISTD -- STD format, indented

OBIB ----- AN, plus Bibliographic Data (original)  
 OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations  
 SIBIB ----- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.

The MAX format is the same as ALL.

The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.  
 HELP FORMATS -- To see detailed descriptions of the predefined formats.  
 ENTER DISPLAY FORMAT (IDE):SEQ

L1 ANSWER 20 OF 20 REGISTRY COPYRIGHT 2009 ACS on STN

SEQ 1 tctgctgttt tctgctgttt t  
 =====

HITS AT: 1-21

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

=&gt; SEQLINK

ENTER TYPE OF LINK (EXACT) OR ?EXACT

ENTER (L1), L# OR ?L1

L2 20 SEQLINK EXACT L1

=&gt; FILE CAPLUS

COST IN U.S. DOLLARS	ENTRY	SINCE FILE SESSION	TOTAL
FULL ESTIMATED COST		17.25	17.47

FILE 'CAPLUS' ENTERED AT 08:30:45 ON 13 JAN 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Jan 2009 VOL 150 ISS 3

FILE LAST UPDATED: 12 Jan 2009 (20090112/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=&gt; S L2

L3 10 L2

=&gt; D BIB AB HITSEQ

L3 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2008:1426958 CAPLUS &lt;&lt;LOGINID::20090113&gt;&gt;

DN 150:24195

TI Phosphate-modified oligonucleotide analogs with enhanced immunostimulatory activity

IN Jurk, Marion; Uhlmann, Eugen

PA Coley Pharmaceutical GmbH, Germany

SO PCT Int. Appl., 71pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2008142513	A2	20081127	WO 2008-IB1206	20080515

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2007-930764P P 20070518

AB The invention relates to oligonucleotides including at least one backbone modification and a pyrimidine-purine dinucleotide. The invention also relates to pharmaceutical compns. and methods of use thereof.

IT \*\*\*1086794-85-5\*\*\* \*\*\*1087356-25-9\*\*\* \*\*\*1087356-26-0\*\*\*  
 \*\*\*1087356-27-1\*\*\* \*\*\*1087356-28-2\*\*\* \*\*\*1087356-29-3\*\*\*  
 \*\*\*1087356-30-6\*\*\* \*\*\*1087356-31-7\*\*\*

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (phosphate-modified oligonucleotide analogs with enhanced immunostimulatory activity)

RN 1086794-85-5 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

NTE modified

SEQ 1 tcgtcggttttcggtcgttt t

RN 1087356-25-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

NTE modified

SEQ 1 tcgtcggttttcggtcgttt t

RN 1087356-26-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

NTE modified

SEQ 1 tcgtcgtttt tcggtcgttt t

RN 1087356-27-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

NTE modified

SEQ 1 tcgtcgtttt tcggtcgttt t

RN 1087356-28-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

NTE modified

SEQ 1 tcgtcgtttt tcggtcgttt t

RN 1087356-29-3 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

NTE modified

SEQ 1 tcgtcgtttt tcggtcgttt t

RN 1087356-30-6 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

NTE modified

SEQ 1 tcgtcgtttt tcggtcgttt t

RN 1087356-31-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

NTE modified

SEQ 1 tcgtcgtttt tcggtcgttt t

=> SEQLINK

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE  
 Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	ENTRY	SINCE FILE SESSION	TOTAL
FULL ESTIMATED COST		10.58	28.05

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	ENTRY	SINCE FILE SESSION	TOTAL
CA SUBSCRIBER PRICE		-0.82	-0.82

FILE 'REGISTRY' ENTERED AT 08:33:05 ON 13 JAN 2009  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 11 JAN 2009 HIGHEST RN 1093181-04-4  
 DICTIONARY FILE UPDATES: 11 JAN 2009 HIGHEST RN 1093181-04-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
 predicted properties as well as tags indicating availability of  
 experimental property data in the original document. For information  
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> S tcgtcgTTTTTCGGTCGTTTT  
 L4 0 TCGTCGTTTTTCGGTCGTTTT

=> s tcgtcgTTTTTCGGTCGTTTT  
 L5 0 TCGTCGTTTTTCGGTCGTTTT

=> S TCGTCGTTTTTCGGTCGTTTT  
 L6 0 TCGTCGTTTTTCGGTCGTTTT

=> S TCGTCGTTTTTCGGTCGTTTT/SQSN  
 L7 35 TCGTCGTTTTTCGGTCGTTTT/SQSN

=> D KWIC SQL 1

L7 ANSWER 1 OF 35 REGISTRY COPYRIGHT 2009 ACS on STN



SEQ 1 tctgctgttt tgggtcgttt t

=====

HITS AT: 1-21

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

SQL 21

=> FILE USPATFULL CAPLUS BIOSIS GENBANK			
COST IN U.S. DOLLARS		SINCE FILE	TOTAL
	ENTRY	SESSION	
FULL ESTIMATED COST		57.52	85.57

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)				SINCE FILE	TOTAL
	ENTRY	SESSION			
CA SUBSCRIBER PRICE		0.00	-0.82		

FILE 'USPATFULL' ENTERED AT 08:38:10 ON 13 JAN 2009

CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CAPLUS' ENTERED AT 08:38:10 ON 13 JAN 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 08:38:10 ON 13 JAN 2009

Copyright (c) 2009 The Thomson Corporation

FILE 'GENBANK' ENTERED AT 08:38:10 ON 13 JAN 2009

=> S L7

L8 24 L7

=> SET DUPORDER FILE

SET COMMAND COMPLETED

=> DUPREM L8

DUPREM IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> DUP REM L8

DUPLICATE IS NOT AVAILABLE IN 'GENBANK'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE  
PROCESSING COMPLETED FOR L8

L9 24 DUP REM L8 (0 DUPLICATES REMOVED)

ANSWERS '1-10' FROM FILE USPATFULL

ANSWERS '11-21' FROM FILE CAPLUS

ANSWERS '22-24' FROM FILE GENBANK

=> D BIB AB HITSEQ

'HITSEQ' IS NOT A VALID FORMAT

In a multifile environment, a format can only be used if it is valid

in at least one of the files. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):D TI PA AB HITRN  
'D' IS NOT A VALID FORMAT

In a multfile environment, a format can only be used if it is valid in at least one of the files. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):TI

L9 ANSWER 1 OF 24 USPATFULL on STN

TI Immunostimulatory nucleic acids

=> D L9 BIB AB 1-10

L9 ANSWER 1 OF 24 USPATFULL on STN

AN 2007:256269 USPATFULL <<LOGINID::20090113>>

TI Immunostimulatory nucleic acids

IN Krieg, Arthur M., Wellesley, MA, UNITED STATES

Lipford, Grayson B., Watertown, MA, UNITED STATES

Samulowitz, Ulrike, Langenfeld, GERMANY, FEDERAL REPUBLIC OF

Vollmer, Jorg, Dusseldorf, GERMANY, FEDERAL REPUBLIC OF

Uhlmann, Eugen, Glashuetten, GERMANY, FEDERAL REPUBLIC OF

Jurk, Marion, Dormagen, GERMANY, FEDERAL REPUBLIC OF

Rankin, Robert, Hemmen, NETHERLANDS

PA Coley Pharmaceutical Group, Inc., Wellesley, MA, UNITED STATES (U.S. corporation)

Coley Pharmaceutical GmbH, Langenfeld, GERMANY, FEDERAL REPUBLIC OF (U.S. corporation)

PI US 20070224210 A1 20070927

A1 US 2006-542845 A1 20061004 (11)

RLJ Continuation of Ser. No. US 2003-644052, filed on 19 Aug 2003, PENDING

PRAI US 2002-404479P 20020819 (60)

US 2002-404820P 20020819 (60)

US 2002-429701P 20021127 (60)

US 2003-447377P 20030214 (60)

DT Utility

FS APPLICATION

LREP WOLF GREENFIELD & SACKS, P.C., 600 ATLANTIC AVENUE, BOSTON, MA, 02210-2206, US

CLMN Number of Claims: 27

ECL Exemplary Claim: 1-94

DRWN 46 Drawing Page(s)

LN.CNT 6547

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a class of soft or semi-soft CpG

immunostimulatory oligonucleotides that are useful for stimulating an immune response.

L9 ANSWER 2 OF 24 USPATFULL on STN

AN 2007:162759 USPATFULL <<LOGINID::20090113>>

TI Immunostimulatory oligoribonucleotides

IN Forsbach, Alexandra, Ratingen, GERMANY, FEDERAL REPUBLIC OF  
 Vollmer, Jorg, Dusseldorf, GERMANY, FEDERAL REPUBLIC OF  
 Lipford, Grayson B., Watertown, MA, UNITED STATES  
 PA Coley Pharmaceutical GmbH, Langenfeld, GERMANY, FEDERAL REPUBLIC OF  
 (non-U.S. corporation)  
 Coley Pharmaceutical Group, Inc., Wellesley, MA, UNITED STATES (non-U.S.  
 corporation)  
 PI US 20070142315 A1 20070621  
 AI US 2006-603978 A1 20061122 (11)  
 PRAI US 2005-739529P 20051125 (60)  
 US 2006-778989P 20060303 (60)  
 DT Utility  
 FS APPLICATION  
 LRFP WOLF GREENFIELD & SACKS, P.C., 600 ATLANTIC AVENUE, BOSTON, MA,  
 02210-2206, US  
 CLMN Number of Claims: 57  
 ECL Exemplary Claim: 1  
 DRWN 13 Drawing Page(s)  
 LN.CNT 4107  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides immunostimulatory compositions and use of those  
 compounds in the preparation of medicaments for the treatment of disease  
 as well as in vitro uses. In particular, the compositions of the  
 invention include immunostimulatory oligoribonucleotides that  
 incorporate a sequence-dependent immunostimulatory sequence motif.  
 Specific modifications involving phosphate linkages, nucleotide analogs,  
 adducts, and combinations thereof are provided. Compositions of the  
 invention, which optionally can include an antigen, can be used alone or  
 together with other treatments to stimulate or enhance an immune  
 response. Also provided are compositions and methods useful for treating  
 a subject having an infection, a cancer, an allergic condition, asthma,  
 airway remodeling, or immunodeficiency. Immunostimulatory  
 oligoribonucleotides of the invention are believed to stimulate  
 Toll-like receptor 8 (TLR8).

L9 ANSWER 3 OF 24 USPATFULL on STN  
 AN 2006:248250 USPATFULL <<LOGINID::20090113>>  
 TI Immunostimulatory oligonucleotides  
 IN Krieg, Arthur M., Wellesley, MA, UNITED STATES  
 Samulowitz, Ulrike, Langenfeld, GERMANY, FEDERAL REPUBLIC OF  
 Vollmer, Jorg, Dusseldorf, GERMANY, FEDERAL REPUBLIC OF  
 PA Coley Pharmaceutical Group, Inc., Wellesley, MA, UNITED STATES (U.S.  
 corporation)  
 Coley Pharmaceutical GmbH, Langenfeld, GERMANY, FEDERAL REPUBLIC OF  
 (non-U.S. corporation)  
 PI US 20060211644 A1 20060921  
 US 20080009455 A9 20080110  
 AI US 2006-361313 A1 20060224 (11)  
 PRAI US 2005-655931P 20050224 (60)  
 DT Utility  
 FS APPLICATION  
 LRFP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE,  
 BOSTON, MA, 02210-2206, US  
 CLMN Number of Claims: 45  
 ECL Exemplary Claim: 1

DRWN 9 Drawing Page(s)

LN.CNT 2871

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a class of short CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. Preferably the short oligonucleotides are soft or semi-soft oligonucleotides.

L9 ANSWER 4 OF 24 USPTAFULL on STN

AN 2005:69478 USPTAFULL <<LOGINID::20090113>>

TI Immunostimulatory nucleic acids

IN Krieg, Arthur M., Wellesley, MA, UNITED STATES  
Samulowitz, Ulrike, Langenfeld, GERMANY, FEDERAL REPUBLIC OF  
Vollmer, Jorg, Dusseldorf, GERMANY, FEDERAL REPUBLIC OF  
Uhlmann, Eugen, Glashuetten, GERMANY, FEDERAL REPUBLIC OF  
Jurk, Marion, Dusseldorf, GERMANY, FEDERAL REPUBLIC OF  
Lipford, Grayson, Watertown, MA, UNITED STATES  
Rankin, Robert, Hemmen, NETHERLANDS

PA Coley Pharmaceutical Group, Inc., Wellesley, MA, UNITED STATES, 02481  
(U.S. corporation)  
Coley Pharmaceutical GmbH, Langenfeld, GERMANY, FEDERAL REPUBLIC OF,  
D-40764 (U.S. corporation)

PI US 20050059619 A1 20050317

AI US 2003-644052 A1 20030819 (10)

PRAI US 2002-404479P 20020819 (60)

US 2002-404820P 20020819 (60)

US 2002-429701P 20021127 (60)

US 2003-447377P 20030214 (60)

DT Utility

FS APPLICATION

LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE,  
BOSTON, MA, 02210-2211

CLMN Number of Claims: 47

ECL Exemplary Claim: 1

DRWN 50 Drawing Page(s)

LN.CNT 6800

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a class of soft or semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response.

L9 ANSWER 5 OF 24 USPTAFULL on STN

AN 2004:299901 USPTAFULL <<LOGINID::20090113>>

TI Immunostimulatory nucleic acid oil-in-water formulations and related methods of use

IN Davis, Heather L., Dunrobin, CANADA  
McCluskie, Michael J., Ottawa, CANADA

PA Coley Pharmaceutical Group, Ltd., Ottawa, CANADA, K1Y 4S1 (non-U.S. corporation)

PI US 20040235770 A1 20041125

AI US 2004-816220 A1 20040401 (10)

PRAI US 2003-461903P 20030410 (60)

US 2003-459920P 20030402 (60)

DT Utility

FS APPLICATION

LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE,  
BOSTON, MA, 02210-2211

CLMN Number of Claims: 23

ECL Exemplary Claim: 1

DRWN 3 Drawing Page(s)

LN.CNT 5381

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention involves methods and compositions of an immunostimulatory nucleic acid in oil-in-water emulsions for topical delivery. The compositions can be used to stimulate immune responses, particularly useful in the prevention and/or treatment of infectious disease and cancer.

L9 ANSWER 6 OF 24 USPATFULL on STN

AN 2004:255150 USPATFULL <<LOGINID::20090113>>

TI Nucleic acid compositions for stimulating immune responses

IN Krieg, Arthur M., Wellesley, MA, UNITED STATES

PA Coley Pharmaceutical Group, Inc., Wellesley, MA (U.S. corporation)

PI US 20040198680 A1 20041007

AI US 2003-613524 A1 20030703 (10)

PRAI US 2002-394091P 20020703 (60)

DT Utility

FS APPLICATION

LREP Maria A. Trevisan, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue,  
Boston, MA, 02210

CLMN Number of Claims: 49

ECL Exemplary Claim: 1

DRWN 9 Drawing Page(s)

LN.CNT 4239

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides an immunostimulatory nucleic acid comprising CpG motifs, and methods of use thereof in stimulating immunity.

L9 ANSWER 7 OF 24 USPATFULL on STN

AN 2004:197343 USPATFULL <<LOGINID::20090113>>

TI Nucleic acid compositions for stimulating immune responses

IN Krieg, Arthur M., Wellesley, MA, UNITED STATES

PA Coley Pharmaceutical Group, Inc., Wellesley, MA (U.S. corporation)

PI US 20040152649 A1 20040805

AI US 2003-613736 A1 20030703 (10)

PRAI US 2002-394164P 20020703 (60)

DT Utility

FS APPLICATION

LREP Maria A. Trevisan, 600 Atlantic Avenue, Boston, MA, 02210

CLMN Number of Claims: 98

ECL Exemplary Claim: 1

DRWN 14 Drawing Page(s)

LN.CNT 4371

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides an immunostimulatory nucleic acid comprising CpG motifs, and methods of use thereof in stimulating immunity.

L9 ANSWER 8 OF 24 USPATFULL on STN

AN 2004:121057 USPATFULL <<LOGINID::20090113>>

TI Nucleic acid compositions for stimulating immune responses

IN Krieg, Arthur M., Wellesley, MA, UNITED STATES  
 PA Coley Pharmaceutical Group, Inc., Wellesley, MA, UNITED STATES, 02481  
 (U.S. corporation)  
 PI US 20040092472 A1 20040513  
 AI US 2003-613228 A1 20030703 (10)  
 PRAI US 2002-394193P 20020703 (60)  
 DT Utility  
 FS APPLICATION  
 LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE,  
 BOSTON, MA, 02210-2211  
 CLMN Number of Claims: 98  
 ECL Exemplary Claim: 1  
 DRWN 16 Drawing Page(s)  
 LN.CNT 4432  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The invention provides an immunostimulatory nucleic acid comprising CpG  
 motifs, and methods of use thereof in stimulating immunity.

L9 ANSWER 9 OF 24 USPATFULL on STN  
 AN 2004:88928 USPATFULL <<LOGINID::20090113>>  
 TI Nucleic acid compositions for stimulating immune responses  
 IN Krieg, Arthur M., Wellesley, MA, UNITED STATES  
 PA Coley Pharmaceutical Group, Inc., Wellesley, MA (U.S. corporation)  
 PI US 20040067905 A1 20040408  
 AI US 2003-613749 A1 20030703 (10)  
 PRAI US 2002-394090P 20020703 (60)  
 DT Utility  
 FS APPLICATION  
 LREP WOLF GREENFIELD & SACKS, PC, FEDERAL RESERVE PLAZA, 600 ATLANTIC AVENUE,  
 BOSTON, MA, 02210-2211  
 CLMN Number of Claims: 98  
 ECL Exemplary Claim: 1  
 DRWN 12 Drawing Page(s)  
 LN.CNT 4438  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The invention provides an immunostimulatory nucleic acid comprising CpG  
 motifs, and methods of use thereof in stimulating immunity.

L9 ANSWER 10 OF 24 USPATFULL on STN  
 AN 2004:70652 USPATFULL <<LOGINID::20090113>>  
 TI Nucleic acid compositions for stimulating immune responses  
 IN Krieg, Arthur M., Wellesley, MA, UNITED STATES  
 PA Coley Pharmaceutical Group, Inc., Wellesley, MA (U.S. corporation)  
 PI US 20040053880 A1 20040318  
 AI US 2003-613739 A1 20030703 (10)  
 PRAI US 2002-393880P 20020703 (60)  
 DT Utility  
 FS APPLICATION  
 LREP Maria A. Trevisan, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue,  
 Boston, MA, 02210  
 CLMN Number of Claims: 98  
 ECL Exemplary Claim: 1  
 DRWN 16 Drawing Page(s)  
 LN.CNT 4668  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides an immunostimulatory nucleic acid comprising CpG motifs, and methods of use thereof in stimulating immunity.

=> D L9 BIB AB 11-24

NO VALID FORMATS ENTERED FOR FILE 'GENBANK'

In a multfile environment, each file must have at least one valid format requested. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):TI

L9 ANSWER 11 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

TI Phosphate-modified oligonucleotide analogs with enhanced immunostimulatory activity

L9 ANSWER 12 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

TI CpG oligonucleotide analogs containing hydrophobic thymidine analogs with enhanced immunostimulatory activity

L9 ANSWER 13 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

TI Phosphorothioate-modified oligodeoxynucleotides inhibit human cytomegalovirus replication by blocking virus entry

L9 ANSWER 14 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

TI Immunostimulatory oligoribonucleotides containing specific sequence motif(s) and targeting the Toll-like receptor 8 pathway

L9 ANSWER 15 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

TI Adjuvanted vaccine for tularemia comprising killed Francisella strain

L9 ANSWER 16 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

TI Immunostimulatory oligonucleotides with stabilized internucleotide linkage for treating cancer, allergy, asthma and infection

L9 ANSWER 17 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

TI Screening for oligonucleotide ligands of toll-like receptors for use as immunomodulators

L9 ANSWER 18 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

TI Immunostimulatory nucleic acid oil-in-water topical emulsions for use with vaccines

L9 ANSWER 19 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

TI Sequences of immunostimulatory oligonucleotides and therapeutic use for immune related diseases

L9 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

TI Immunostimulatory nucleic acids for enhancing immune responses to antigen vaccines against cancer, infection, allergy and autoimmune disease

L9 ANSWER 21 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

TI Diagnosis and therapy of diseases associated with signal transduction by detection of single nucleotide polymorphism and cytosine methylation in chemically modified genomic DNA

L9 ANSWER 22 OF 24 GENBANK.RTM. COPYRIGHT 2009 on STN

TITLE (TI): Methods and products for identification and assessment  
of tlr ligands

L9 ANSWER 23 OF 24 GENBANK.RTM. COPYRIGHT 2009 on STN

TITLE (TI): Immunostimulatory nucleic acid oil-in-water  
formulations and related methods of use

L9 ANSWER 24 OF 24 GENBANK.RTM. COPYRIGHT 2009 on STN

TITLE (TI): Diagnosis of diseases associated with signal  
transduction

=> D L9 BIB AB 11-21

L9 ANSWER 11 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2008:1426958 CAPLUS <<LOGINID::20090113>>

DN 150:24195

TI Phosphate-modified oligonucleotide analogs with enhanced immunostimulatory  
activity

IN Jurk, Marion; Uhlmann, Eugen

PA Coley Pharmaceutical GmbH, Germany

SO PCT Int. Appl., 71pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI WO 2008142513	A2	20081127	WO 2008-IB1206	20080515
------------------	----	----------	----------------	----------

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,  
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,  
FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,  
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,  
PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,  
IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,  
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,  
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2007-930764P P 20070518

AB The invention relates to oligonucleotides including at least one backbone  
modification and a pyrimidine-purine dinucleotide. The invention also  
relates to pharmaceutical compns. and methods of use thereof.

L9 ANSWER 12 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2008:705793 CAPLUS <<LOGINID::20090113>>

DN 149:77378

TI CpG oligonucleotide analogs containing hydrophobic thymidine analogs with



enhanced immunostimulatory activity

IN Debelak, Harald; Uhlmann, Eugen; Jurk, Marion

PA Coley Pharmaceutical G.m.b.H., Germany

SO PCT Int. Appl., 127pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2008068638	A2	20080612	WO 2007-IB4389	20070925
WO 2008068638	A3	20081113		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRAI US 2006-847811P P 20060927

OS MARPAT 149:77378

AB The authors disclose oligonucleotides including at least one lipophilic substituted nucleotide analog and a pyrimidine-purine dinucleotide. In one example, the oligonucleotides, comprising hydrophobic thymidine base analogs 5' and 3' of the CpG motif, shown an enhanced ability to elicit Toll-like receptor 9-dependent responses.

L9 ANSWER 13 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2008:292654 CAPLUS <<LOGINID::20090113>>

DN 148:509462

TI Phosphorothioate-modified oligodeoxynucleotides inhibit human cytomegalovirus replication by blocking virus entry

AU Luginani, Anna; Caposio, Patrizia; Landolfo, Santo; Gribo, Giorgio

CS Department of Public Health and Microbiology, University of Turin, Turin, Italy

SO Antimicrobial Agents and Chemotherapy (2008), 52(3), 1111-1120

CODEN: AMACCCQ; ISSN: 0066-4804

PB American Society for Microbiology

DT Journal

LA English

AB Studies in animal models have provided evidence that Toll-like receptor 9 (TLR9) agonists, such as synthetic oligodeoxynucleotides (ODNs) that contain immunostimulatory deoxycytidyl-deoxyguanosine (CpG) motifs (CpG ODNs), protect against a wide range of viral pathogens. This antiviral activity has been suggested to be indirect and secondary to CpG-induced cytokines and inflammatory responses triggered through TLR9 activation. However, few studies have addressed the potential of CpG ODNs as direct antiviral agents. Here, the authors report on the ability of some CpG ODNs to directly suppress, almost completely, human cytomegalovirus (HCMV) replication in both primary fibroblasts and endothelial cells. Murine CMV

replication was inhibited as well, whereas no inhibition was obsd. for herpes simplex virus type 1, adenovirus, or vesicular stomatitis virus. The antiviral activity of these ODNs was significantly reduced when they were added after virus adsorption, indicating that their action may be primarily targeted to the very early phases of the HCMV cycle. In fact, the B-class prototype CpG ODN 2006 effectively prevented the nuclear localization of pp65 and input viral DNA, which suggests that it inhibits HCMV entry. Moreover, a CpG 2006 control, ODN 2137 without CpG motifs, also showed a potent inhibitory activity on the HCMV entry phase, indicating that the anticytomegaloviral activity is independent of the CpG motif. In contrast, a phosphodiester version of CpG 2006 showed reduced antiviral activity, indicating that the inhibitory activity is dependent on the phosphorothioate backbone of the ODN. These results suggest that this yet-unrecognized activity of CpG ODNs may be of interest in the development of novel anticytomegaloviral mols.

RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 14 OF 24 CAPLUS COPYRIGHT 2009 ACS ON STN

AN 2007:585028 CAPLUS <<LOGINID::20090113>>

DN 147:8414

TI Immunostimulatory oligoribonucleotides containing specific sequence motif(s) and targeting the Toll-like receptor 8 pathway

IN Forsbach, Alexandra; Vollmer, Joerg; Lipford, Grayson B.

PA Coley Pharmaceutical G.m.b.H., Germany; Coley Pharmaceutical Group, Inc.

SO PCT Int. Appl., 143pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007062107	A2	20070531	WO 2006-US45183	20061122
WO 2007062107	A3	20070712		
W: AE, AG, AI, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2006318464	A1	20070531	AU 2006-318464	20061122
CA 2630738	A1	20070531	CA 2006-2630738	20061122
US 20070142315	A1	20070621	US 2006-603978	20061122
EP 1957647	A2	20080820	EP 2006-838257	20061122
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
IN 2008DN04423	A	20080815	IN 2008-DN4423	20080523
CN 101331229	A	20081224	CN 2006-80044030	20080526
KR 2008072934	A	20080807	KR 2008-715356	20080624

PRAI US 2005-739529P P 20051125  
 US 2006-778989P P 20060303  
 WO 2006-US45183 W 20061122

AB The invention provides immunostimulatory compns. and use of those compns. in the prepn. of medicaments for the treatment of disease as well as in vitro uses. In particular, the compns. of the invention include immunostimulatory oligoribonucleotides that incorporate a sequence-dependent immunostimulatory sequence motif. Certain sequence-specific RNA motifs, preferably contg. AU-rich sequences, are discovered to be immunostimulatory, stimulating an immune response through Toll-like receptor 8 (TLR8). Differences between interferon-alpha., tumor necrosis factor-alpha., interferon-gamma., and interleukin-12 prodn. are obsd. in oligonucleotides contg. AU vs. GU repetitions. The AU-rich immunostimulatory oligoribonucleotides produce a strong pro-inflammatory cytokine response, with the exception of interferon-alpha. and related molts. Interferon-alpha. is diminished or lacking upon stimulation with these oligoribonucleotides. Thus, compns. of the invention, which optionally can include an antigen, can be used alone or together with other treatments to stimulate or enhance an immune response. Also provided are compns. and methods useful for treating a subject having an infection, a cancer, an allergic condition, asthma, airway remodeling, or immunodeficiency.

L9 ANSWER 15 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2007:284126 CAPLUS <<LOGINID::20090113>>  
 DN 146:336431  
 TI Adjuvanted vaccine for tularemia comprising killed Francisella strain  
 IN Eyles, James Edward; Hartley, Margaret Gillian  
 PA The Secretary of State for Defence, UK  
 SO PCT Int. Appl., 32pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007028985	A2	20070315	WO 2006-GB3296	20060907
WO 2007028985	A3	20070503		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
GB 2443591	A	20080507	GB 2008-4079	20060907
EP 1924279	A2	20080528	EP 2006-779315	20060907
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRAI GB 2005-18203	A	20050907		

GB 2005-18305 A 20050908  
 WO 2006-GB3296 W 20060907

AB This invention relates to new immunogenic compns. and vaccines suitable for preventing or treating tularemia. The strain used by the inventors is F. tularensis LVS (live vaccine strain), killed by irradn. Three different adjuvants were used in the examples: ISCOM (AbISCO-100), CpG 7909 (CpG oligodeoxynucleotide), and Alhydrogel (Alum). Mice were immunized either s.c. or i.m. with  $1.5 \times 10^9$  CFU LVS. The inventors performed the anal. of antibody response and challenge studies. The ELISPOT assay showed that immunization with LVS produced a cytokine recall response profile consistent with a biased Th1 response (high interferon gamma. formation and low interleukin-4 formation).

L9 ANSWER 16 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2006:888480 CAPLUS <<LOGINID::20090113>>

DN 145:291047

TI Immunostimulatory oligonucleotides with stabilized internucleotide linkage for treating cancer, allergy, asthma and infection

IN Krieg, Arthur M.; Samulowitz, Ulrike; Vollmer, Joerg

PA Coley Pharmaceutical Group, Inc., USA; Coley Pharmaceutical GmbH

SO PCT Int. Appl., 93pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006091915	A2	20060831	WO 2006-US6778	20060224
WO 2006091915	A3	20070315		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006216493	A1	20060831	AU 2006-216493	20060224
AU 2006216493	A2	20080320		
AU 2006216493	A9	20080403		
CA 2598992	A1	20060831	CA 2006-2598992	20060224
US 20060211644	A1	20060921	US 2006-361313	20060224
US 20080009455	A9	20080110		
EP 1851314	A2	20071107	EP 2006-736157	20060224
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 2008531018	T	20080814	JP 2007-557215	20060224
CN 101160401	A	20080409	CN 2006-80012811	20071017
PRAI US 2005-655931P	P	20050224		
WO 2006-US6778	W	20060224		

AB The invention relates to a class of short CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. Preferably the short oligonucleotides are soft or semi-soft oligonucleotides.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 17 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2004:934524 CAPLUS <<LOGINID::20090113>>

DN 141:394071

TI Screening for oligonucleotide ligands of toll-like receptors for use as immunomodulators

IN Vollmer, Joerg; Jurk, Marion; Lipford, Grayson B.; Schetter, Christian; Forsbach, Alexandra; Krieg, Arthur M.

PA Coley Pharmaceutical G.m.b.H., Germany; Coley Pharmaceutical Group, Inc.

SO PCT Int. Appl., 340 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004094671	A2	20041104	WO 2004-US12788	20040422
WO 2004094671	A9	20050127		
WO 2004094671	A3	20050922		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1631687	A2	20060308	EP 2004-760178	20040422
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI US 2003-464586P	P	20030422		
US 2003-464586P	P	20030422		
WO 2004-US12788	W	20040422		

AB Screening methods to identify ligands, esp. oligonucleotides, for Toll-like receptors that may be useful as immunomodulators. These methods may also be used to assay the biol. activity of preps. contg. a known TLR ligand, e.g. in quality control. The methods involve testing responses induced by activation of a Toll-like receptor, such as changes in cell surface markers or patterns of gene expression, or the use of a reporter gene regulated by a promoter controlled by a.

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 18 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2004:857435 CAPLUS <<LOGINID::20090113>>

DN 141:337779

TI Immunostimulatory nucleic acid oil-in-water topical emulsions for use with vaccines

IN Davis, Heather L.; McCluskie, Michael J.

PA Coley Pharmaceutical Group, Ltd., Can.

SO PCT Int. Appl., 188 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004087203	A2	20041014	WO 2004-IB1371	20040401
WO 2004087203	A3	20041223		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004226605	A1	20041014	AU 2004-226605	20040401
CA 2521050	A1	20041014	CA 2004-2521050	20040401
US 20040235770	A1	20041125	US 2004-816220	20040401
EP 1608403	A2	20051228	EP 2004-725130	20040401
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI US 2003-459920P	P	20030402		
US 2003-461903P	P	20030410		
WO 2004-IB1371	W	20040401		

AB Oil-in-water emulsions contg. an an immunostimulatory nucleic acid, such as CpG oligonucleotide, are described for topical administration in the prevention and treatment of infection. The emulsion may also contain other therapeutic agents, including antiviral, antibacterial or antitumor agents. The compus. can be used to stimulate immune responses, particularly useful in the prevention and/or treatment of infectious disease and cancer. In tests with mice infected with human herpesvirus 2, immunostimulation against the virus was superior when the nucleic acids were delivered in an oil-in-water emulsion. Water-in-oil emulsions were no more effective than control treatments.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 19 OF 24 CAPLUS COPYRIGHT 2009 ACS ON STN

AN 2004:162829 CAPLUS <<LOGINID::20090113>>

DN 140:230578

TI Sequences of immunostimulatory oligonucleotides and therapeutic use for immune related diseases

IN Krieg, Arthur M.; Samulowitz, Ulrike; Vollmer, Joerg; Uhlmann, Eugen; Jurk, Marion; Lipford, Grayson; Rankin, Robert

PA Coley Pharmaceutical Group, Inc., USA; Coley Pharmaceutical GmbH

SO PCT Int. Appl., 276 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004016805	A2	20040226	WO 2003-US25935	20030819
WO 2004016805	A9	20040819		
WO 2004016805	A3	20050217		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2493753	A1	20040226	CA 2003-2493753	20030819
AU 2003259916	A1	20040303	AU 2003-259916	20030819
US 20050059619	A1	20050317	US 2003-644052	20030819
EP 1538904	A2	20050615	EP 2003-788643	20030819
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1688192	A	20051026	CN 2003-824039	20030819
JP 20060508693	T	20060316	JP 2005-502069	20030819
BR 2003013414	A	20070731	BR 2003-13414	20030819
NZ 538001	A	20080530	NZ 2003-538001	20030819
RU 2338750	C2	20081120	RU 2005-107708	20030819
IN 2005KN00167	A	20060421	IN 2005-KN167	20050210
NO 2005001469	A	20050519	NO 2005-1469	20050318
US 20070224210	A1	20070927	US 2006-542845	20061004
IN 2007KN02317	A	20080801	IN 2007-KN2317	20070622
KR 2008011247	A	20080131	KR 2008-701536	20080118
PRAI US 2002-404479P	P	20020819		
US 2002-404820P	P	20020819		
US 2002-429701P	P	20021127		
US 2003-447377P	P	20030214		
US 2003-644052	A1	20030819		
WO 2003-US25935	W	20030819		
IN 2005-KN167	A3	20050210		
KR 2005-702841	A3	20050218		

OS MARPAT 140:230578

AB The invention relates to a class of soft or semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2004:41608 CAPLUS &lt;&lt;LOGINID::20090113&gt;&gt;

DN 140:110112

TI Immunostimulatory nucleic acids for enhancing immune responses to antigen vaccines against cancer, infection, allergy and autoimmune disease

IN Krieg, Arthur M.  
 PA Coley Pharmaceutical Group, Inc., USA  
 SO PCT Int. Appl., 257 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004005476	A2	20040115	WO 2003-US21113	20030703
WO 2004005476	A3	20040521		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2494508	A1	20040115	CA 2003-2494508	20030703
AU 2003247880	A1	20040123	AU 2003-247880	20030703
US 20040053880	A1	20040318	US 2003-613739	20030703
US 20040067905	A1	20040408	US 2003-613749	20030703
US 20040092472	A1	20040513	US 2003-613228	20030703
US 20040152649	A1	20040805	US 2003-613736	20030703
US 20040198680	A1	20041007	US 2003-613524	20030703
EP 1551221	A2	20050713	EP 2003-763239	20030703
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1678188	A	20051005	CN 2003-820863	20030703
JP 2005532067	T	20051027	JP 2004-519911	20030703
IN 2005KN00122	A	20060106	IN 2005-KN122	20050202
PRAI US 2002-393880P	P	20020703		
US 2002-394090P	P	20020703		
US 2002-394091P	P	20020703		
US 2002-394164P	P	20020703		
US 2002-394193P	P	20020703		
WO 2003-US21113	W	20030703		

AB The invention provides immunostimulatory nucleic acids comprising CpG motifs, and methods of use thereof in stimulating immunity. The immunostimulatory nucleic acids are T-rich, poly-T-contg. or poly-G-contg. sequences. The immunostimulatory nucleic acids are formulated in nutritional supplement, capsule, pill, sublingual tablet, parenteral, local, sustained-release, mucosal, oral, nasal, rectal, vaginal, ocular or systemic forms for administration. The immunostimulatory nucleic acids are esp. useful as adjuvant for vaccines against cancer, infection, allergy and autoimmune disease.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 21 OF 24 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2002:582203 CAPLUS <<LOGINID::20090113>>  
 Correction of: 2002:10728



DN 137:104768

Correction of: 136:65179

TI Diagnosis and therapy of diseases associated with signal transduction by  
detection of single nucleotide polymorphism and cytosine methylation in  
chemically modified genomic DNA

IN Olek, Alexander; Piepenbrock, Christian; Berlin, Kurt

PA Epigenomics Ag, Germany

SO PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DT Patent

LA English

FANCNT 69

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002000926	A2	20020103	WO 2001-EP7472	20010629
	WO 2002000926	A3	20021121		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	DE 10032529	A1	20020207	DE 2000-10032529	20000630
	AU 2001077487	A	20011023	AU 2001-77487	20010406
	EP 1360319	A2	20031112	EP 2001-955278	20010406
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	EP 2000544	A1	20081210	EP 2008-12765	20010406
	R:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR			
	AU 2001089617	A	20020108	AU 2001-89617	20010629
	EP 1297185	A2	20030402	EP 2001-969326	20010629
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	DE 20121961	U1	20040129	DE 2001-20121961	20010629
	DE 20121971	U1	20040205	DE 2001-20121971	20010629
	DE 20121979	U1	20040205	DE 2001-20121979	20010629
	DE 20121966	U1	20031224	DE 2001-20121966	20010702
	DE 20121963	U1	20040129	DE 2001-20121963	20010702
	DE 20121967	U1	20040129	DE 2001-20121967	20010702
	DE 20121975	U1	20040219	DE 2001-20121975	20010702
	DE 20121978	U1	20040219	DE 2001-20121978	20010702
	EP 1676927	A2	20060705	EP 2006-2091	20010702
	EP 1676927	A3	20061206		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR			
	EP 1942197	A1	20080709	EP 2007-119103	20010901
	R:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR			
	AT 339520	T	20061015	AT 2002-90203	20020605
	ES 2272636	T3	20070501	ES 2002-90203	20020605
	US 20040067491	A1	20040408	US 2003-240454	20030311

AU 2003204553	A1	20040108	AU 2003-204553	20030605
AU 2003204553	B2	20071129		
JP 2004008217	A	20040115	JP 2003-160375	20030605
US 20040023279	A1	20040205	US 2003-455212	20030605
NZ 541308	A	20061222	NZ 2005-541308	20050715
AU 2006213968	A1	20061019	AU 2006-213968	20060915
PRAI DE 2000-10032529	A	20000630		
DE 2000-10043826	A	20000901		
DE 2000-10019058	A	20000406		
DE 2000-10019173	A	20000407		
DE 2000-10044543	A	20000905		
AU 2001-275663	A	20010406		
AU 2001-75663	A	20010406		
EP 2001-969303	A3	20010406		
WO 2001-EP4016	W	20010406		
WO 2001-EP7472	W	20010629		
EP 2001-962813	A3	20010702		
EP 2001-967115	A	20010702		
EP 2001-980315	A3	20010901		
NZ 2001-524229	A1	20010901		
EP 2002-90203	A	20020605		

AB The invention relates to chem. modified genomic sequences of genes assocd. with signal transduction, an oligonucleotide directed against said sequence and/or PNA oligomers for the detection of the methylation state of cytosine of genes assocd. with signal transduction. The present invention is based on the discovery that cytosine methylations patterns in genomic DNA are particularly suitable for diagnosis and/or therapy of diseases assocd. with signal transduction. Thus, the chem. Modified genomic sequences of genes assocd. with signal transduction, and oligonucleotides and/or peptide nucleic acid oligomers for detecting the cytosine methylation state of signal transduction genes are provided. Specific reaction of bisulfite and subsequent alk. hydrolysis converts cytosine to uracil, which corresponds to thymidine in its base pairing behavior. However, 5-methylcytosine remains unmodified under these conditions. Consequently, the original DNA is converted in such a manner that methylcytosine, which originally could not be distinguished from cytosine by its hybridization behavior, can now be detected as the only remaining cytosine using "normal" mol. biol. techniques. The oligomer probes according to the present invention, contg. at least one CpG dinucleotide, constitute important and effective tools which make it possible to ascertain the genetic and epigenetic parameters of genes assocd. with signal transduction. The invention is exemplified by gene AR in which a specific CG-position is analyzed for methylation. The Sequence Listing was provided as an electronic file, but was not made available in the release of this patent.

=> D.L9 BIB AB 22-24

'BIB' IS NOT A VALID FORMAT

'AB' IS NOT A VALID FORMAT

In a multifile environment, a format can only be used if it is valid in at least one of the files. Refer to file specific help messages or the STNGUIDE file for information on formats available in individual files.

REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):ALL

L9 ANSWER 22 OF 24 GENBANK.RTM. COPYRIGHT 2009 on STN

LOCUS (LOC): CQ903957 GenBank (R)  
 GenBank ACC. NO. (GBN): CQ903957  
 GenBank VERSION (VER): CQ903957.1 GI:55785349  
 CAS REGISTRY NO. (RN): \*\*\*784072-70-4\*\*\*  
 SEQUENCE LENGTH (SQL): 21  
 MOLECULE TYPE (CT): DNA; linear  
 DIVISION CODE (CD): Patent  
 DATE (DATE): 16 Nov 2004  
 DEFINITION (DEF): Sequence 143 from Patent WO2004094671.  
 SOURCE: synthetic construct  
 ORGANISM (ORGN): synthetic construct  
 other sequences; artificial sequences  
 REFERENCE: 1  
 AUTHOR (AU): Vollmer,J.; Jurk,M.; Lipford,G.B.; Schetter,C.;  
 Forsbach,A.; Krieg,A.M.  
 TITLE (TI): Methods and products for identification and assessment  
 of tlr ligands  
 JOURNAL (SO): Patent: WO 2004094671-A 143 04-NOV-2004; Coley  
 Pharmaceutical GmbH (DE); Coley Pharmaceutical Group,  
 Inc. (US)

## FEATURES (FEAT):

Feature Key	Location	Qualifier
source	1..21	/organism="synthetic construct" /mol-type="unassigned DNA" /db-xref="taxon:32630" /note="Immunostimulatory nucleic acid"

## SEQUENCE (SEQ):

1 tcgtcgttt tcggtcgttt t

L9 ANSWER 23 OF 24 GENBANK.RTM. COPYRIGHT 2009 on STN

LOCUS (LOC): CQ892106 GenBank (R)  
 GenBank ACC. NO. (GBN): CQ892106  
 GenBank VERSION (VER): CQ892106.1 GI:55164664  
 CAS REGISTRY NO. (RN): \*\*\*774441-79-1\*\*\*  
 SEQUENCE LENGTH (SQL): 21  
 MOLECULE TYPE (CT): DNA; linear  
 DIVISION CODE (CD): Patent  
 DATE (DATE): 1 Nov 2004  
 DEFINITION (DEF): Sequence 149 from Patent WO2004087203.  
 SOURCE: synthetic construct  
 ORGANISM (ORGN): synthetic construct  
 other sequences; artificial sequences  
 REFERENCE: 1  
 AUTHOR (AU): Davis,H.L.; Mccluskie,M.J.  
 TITLE (TI): Immunostimulatory nucleic acid oil-in-water  
 formulations and related methods of use  
 JOURNAL (SO): Patent: WO 2004087203-A 149 14-OCT-2004; Coley

Pharmaceutical Group, Ltd. (CA)

## FEATURES (FEAT):

Feature Key	Location	Qualifier
source	1..21	/organism="synthetic construct" /mol-type="unassigned DNA" /db-xref="taxon:32630" /note="Oligonucleotide"

## SEQUENCE (SEQ):

1 tcgtcgtttt tcggtcgttt t

L9 ANSWER 24 OF 24 GENBANK.RTM. COPYRIGHT 2009 on STN

LOCUS (LOC): AX344227 GenBank (R)

GenBank ACC. NO. (GBN): AX344227

GenBank VERSION (VER): AX344227.1 GI:18492115

CAS REGISTRY NO. (RN): \*\*\*392439-15-5\*\*\*

SEQUENCE LENGTH (SQL): 13133

MOLECULE TYPE (CT): DNA; linear

DIVISION CODE (CI): Patent

DATE (DATE): 1 Feb 2002

DEFINITION (DEF): Sequence 74 from Patent WO0200926.

SOURCE: synthetic construct

ORGANISM (ORGN): synthetic construct  
other sequences; artificial sequences

REFERENCE: 1

AUTHOR (AU): Olek,A.; Piepenbrock,C.; Berlin,K.

TITLE (TI): Diagnosis of diseases associated with signal  
transductionJOURNAL (SO): Patent: WO 0200926-A 74 03-JAN-2002; Epigenomics AG  
(DE)

## FEATURES (FEAT):

Feature Key	Location	Qualifier
source	1..13133	/organism="synthetic construct" /mol-type="unassigned DNA" /db-xref="taxon:32630" /note="chemically treated genomic DNA (Homo sapiens)"

## SEQUENCE (SEQ):

1 ttgggaattt agataggaaa tataaataga aaagaagtgg tgtttgtta aatgggtgat  
 61 aagtaatttt taataatatt atcgttttta attttatatt tataaaattt tatttggttt  
 121 gagtaaaagt tataaatatt gtgattttga aaataggatt ttataaatgt tatgtttaat  
 181 agataaagat gtttgttgta tatatttagg gttttttacg gagatagaga tttaattttt  
 241 attattttat atttaatttt tagtataggg ttgggtatat tatagggtgt ttatttaatt  
 301 tatatttgat ataaaaatga aataggatat agaaaaaat atgtatatat aagattttat  
 361 gttgggtttt ttatttttag attatagtat tttttatatt ttatttagta gtttttaatt  
 421 atgaagaatg ggattatggt tgttttgttt attatttttt tttaattatt tagagtttta  
 481 tttagaaaat attttattat tagtattttt tttttttt aaattttgat gaaatttaag  
 541 tgtatatatg atttagtgat aaaaataaaa atttttgtgt tttagattgg aaagattttt  
 601 atgtatagtg gtattatagt attttatgaa tttttgattt atttttaaaa gtttttaggt

661 tttatttaatt gtaataatta ttaaggat tagtttaat aaattaagta acgattat  
 721 ttttttgggt ttttcggag ggttttagtg ttatgttt tgaagatgt tattttata  
 781 agtttggtgg atatttagat ttttaaatg gaatttaag aagtaattt ttttttaggt  
 841 atgtatgta ttttgaata ttttgitta tattttata atgtgtgtaa ttaaggatt  
 901 ttatgtttt atgagaatt ttttgggat ttttttaag tattatggt gttagaggt  
 961 aaggggtagg agaggatgg tagttaggat ttttttag ttagaattt ttttttggga  
 1021 taatttttag ttttaagta gtttgtagg tgaatttgt agaaattt atattttt  
 1081 gttattataa ttattttat ttatgaatt gttataata gaaggttgt ttttaagtg  
 1141 atagagtitt tttttttag gaatttataa taatttagat gaagtttat gttattagta  
 1201 tttttttt tattttttt taaattttt tttgggtt ttatattta ttgaagagt  
 1261 agaagggttt tttattatga atatagtat ttaaatatg atttgggaat atttggatta  
 1321 taaatagaa ttttaattt ttttttag tagattaaga cgtttatat ttttttgg  
 1381 gatataaat atgtataatg attatgtgga gtgtgagtt tttttgt tattttta  
 1441 taaaataaaa tagaagataa tatttgggt tttttgatt gttatttat aggtttaggg  
 1501 atattttt tttagattat aattgagtt tttttata ttatagatg atattttg  
 1561 ttatgtgtat ttattttaa taagatagt tagaaaggtt attttatt ttttttaggt  
 1621 taaagtaggg gtattttata aaatgaatt aggttaagtt tgggtatata taaagaggt  
 1681 ataggttgt ttatgtttt ttttttag ttctgttt tttatttt ttttttat  
 1741 gttgttttt aaatataga taataaagg gtttgaata aaatatttt ttttttaga  
 1801 attttttt tttagatgga gttgtgatat tttagtaga aaatttatat tattgtata  
 1861 taattttataa aaagtataaa gttttttt aggtataaat taattttggg gtttagaga  
 1921 ttttaaaaaa tatagttaa tagaaataag tttagaaat ttattttag taattttgt  
 1981 ttctgtata atttaataa tttattataa ttttttagta attaaatta acgagattga  
 2041 taagaacga ttattttta tatttttaatt tttttttt tgggtttt tttagtatta  
 2101 attattatt aaatttaggt ggtttaaga gtttttagg gtttaattt cgaattttt  
 2161 ggtttttat ttataaat ttttgaatt gaatttgaat atagttaggg tttagaat  
 2221 ttttttaggt tttaggttg cgtatttgt tttaggttt agattttta aggtttat  
 2281 tttagtggg aagatatata tatttaata tctagtagtt tttttttta taagtaatt  
 2341 aaatttaatt tatgtattt ttataaatt agtttttat tttaaat ttttttt  
 2401 gataaaaaaa aggtttttt ttatgtgtt atttaggta ttatttgcg aatgaattt  
 2461 tagtttgtg ttttggaaa atttaaat ttttttat ttttaagt attaagaaga  
 2521 ttattatta ttatttagg ttttttat taatattgt ttattttat ttttagat  
 2581 ttttttagg gataattgag gtatagtct aatagtttt ttttttta agtttagaat  
 2641 ttttaaat ttttttat agtttttta gattttgat taaagtttt aatttagat  
 2701 taattttgt ttttttag gtttgtgtt gtaatttat ttatagtta atgaagaat  
 2761 ttattagttaa gaataaagg ttttaaaag tagaggttaa atgacggag ttttttat  
 2821 ttatttaatt attgtattt ttttttta gagaataaag tttagatgt taggtttaa  
 2881 aaatttatat attttttat atttttgt tttagtgag gtttaggtt atagttagg  
 2941 attttagt agatatata taatgaatt agttttata ttatttaaat gtgtattta  
 3001 ggttaattta tttatttt gttatttta gtttttgt ttgaataaa aagtaataa  
 3061 agttatttta tttaggttt taggggaatt aaataaggta atagtgtaa aggttttagt  
 3121 agttagttaa tttagatatt attattgtt tttagata tttttgtaa tttttttt  
 3181 taattttagg ttattttt ttattttat ttttttat ttgaattgt ttatttag  
 3241 atgtattat ttgttgtga gtaatttag ggtgggttt tttttatgt tttaagtt  
 3301 taattaat aaatttaggt atatagtaa tttaataa atattttgg gttggaagaa  
 3361 tatagttaa tagattttt ttgtaattt tttttttt tggagtgtt ttgagaatt  
 3421 atattgtga tttttaag gaattatga gtttaggtt agggatttaa gaaacgttt  
 3481 tttgtattta agtttaaga cgttaggtt gtatgtgatt cgtatagatt tggaggttaa  
 3541 ggtattttta gtttaagta tttagtagt atatttaatt taatttagt aaaaattat  
 3601 tttaataaat atttaatta aaatttaaa agtaatatat gtaatttaa aatttttta  
 3661 gatgttagg attatttga gaagttttag taaagaaga tttagaatt taatttgt  
 3721 aggtatttaa aatttaatt aagttaaaa gttataata ttgatttata aaaaatggg  
 3781 tagagatgag gttgggggtg ttgggggtt agaaattga gaattttt agaatagta  
 3841 tttaagatt atatttaaa tttaaggata ttaaaaatt ttttttttag tttagttt  
 3901 tgaagttag gatttaggt tatttgata tttaattga tagtatagt ttgttatat

3961 ttaaaaaat atattgaggt cgggtatagg eggttaatt tgaatttta gtaatttggg  
 4021 aggttgaggt aggtggatta ttgaggtta ggagttata ataatllgg ttaatatggt  
 4081 gaaatttat ttattataa aataataaaa ttagttaggt atgttgccgg gttttgttaa  
 4141 ttattatatt ttgggtgggt aaggttaagg aalcgttga attlcggagg cegaggttgt  
 4201 agtgcgcga gatggagtta ttgatatta gttgggttaa tagagtgaaga ttccgttta  
 4261 aaaaaataaa aaaaaataaa aaaaaataa aaaaataat ataatgtta aatatgttat  
 4321 aatttatggg ttcaaatga gagatttga aaggttttt ttattattaa gatttttgg  
 4381 ataaatatt atataaaaat aatagttaa ttagtgtgt agttttatt ttittataa  
 4441 agaaatggt aatatagata tatttatgt tgaataatgt ttggcgctt taaaatttt  
 4501 ttgnaagtta tttagaaat gttgatagt attagttaa tagaatgag tttaaaaga  
 4561 ttggaatttt agtttttt taatatltt gatagtltgt gtgttttgt tagaagaaga  
 4621 aatgttatt ttittttt taaaatatt ttatttta aatgtgtat tttaattga  
 4681 atattttt aawgttaaaa ttgataatg gatgttttta tatagtaaaa tagttataaa  
 4741 agttatatat attttaaat ttgtaattt aaaaatttt ttataataaa ttataattta  
 4801 atattaafag aaaaataata ggaagtgaaga tagtgattgg gtatatttt ttittata  
 4861 taatatgaaa taattaaggt gtaaaaataa ttatatatgg agatataaaa taaaagggtta  
 4921 atggtttga taatttttaa agttataat tttaataat atatatttaa ttgtttatt  
 4981 atattattgt taagagaaga ttggtgaag ttattatgt aagattatt ttattttt  
 5041 aatgttttt cgtttttt ttatttga agtttttt aggttgaatt atttggaaa  
 5101 taataattaa aattttata aatttgata gatataagg aatatgatt taaaaggtt  
 5161 ttgtattta taatgggtt agtataatt ttagaatta gtatgtttta ttatattt  
 5221 aaaaattag ttgagaggat gtatgtttt atttgggtt tgaatgaat tgggtggga  
 5281 attttatga aattgttat ttctgttag ttgttttt ttattataaa ttgaagaat  
 5341 agaatagat aattttgtg gttttgtaa ttitttgt attagaat ttgtattt  
 5401 atagaataa aataaaatt aattattat cgaatttaa attatttt taaagttaa  
 5461 gtatttaata ataatagta tatcgaagt ttatatatc taaaaataa gtaaatllgg  
 5521 tatagtat agtaaaatatt aggttttat tatgaggagt attgagaagt atattcgtat  
 5581 ttitttttt ttgtgtatt ataggtttt tttagtgg agatttgcg ttatttat  
 5641 ttattata ttattttaa ttgtaagag gtttgatta agtaaatgt attttata  
 5701 aatgggaatt tatagttaa taaatagtt ttittttag ttatattat gtatgtgat  
 5761 tatattaata tatagttaa aatgggat tatatttt aattgttag atgatttaa  
 5821 aaaaaaaat taaatttt aaaaataag gtatgtttt aatatattt gtgataaga  
 5881 tatttaatag taatatag aattttatt ttattatat tatttatagt ttaatatagg  
 5941 ttagttaatt ttgttgaat gaattttag ttltgggat tagatgtgt aggatagaga  
 6001 gatagataga gggaggggga agatagtaat agtaataaaa taattttta cgaatttgt  
 6061 atatatttt ttagttttaa taggttgaat tatagttag atatttttt atagttttt  
 6121 gataataag ttitttata atatatgtt tttagattat ttittgtag atcgagagatg  
 6181 gttttttt taagaattta attttatt agtaataaaa ataatttt agtaatttt  
 6241 ttatatag aattattta gttgtttt ttggaaaaat taattggaaa aaaaagattt  
 6301 ttaattatt atttttita agttagatt ttitttagt ttgttttat taattaggg  
 6361 ttattttgg gatgtagaaa aagttatgt tttagtcga atttagttg ttagtttcg  
 6421 tagttattag taattagtt tacgttgggt ttittttt tagagattat agtatttgt  
 6481 aggtgtttt ttittttt tttaagta acgtttgtt ttittttt aataattgtt  
 6541 aattgtaga ttattatgg gtgtgttgt ttgatttgg cggcggttt ttatttgtt  
 6601 aatgttatt aaaaatttt ttgtgttaa attgtatga ttataaaat agtttatat  
 6661 acgcggggga taattggga ttgttttt ttgttggagt tagtttggg aggtttttg  
 6721 ggggcatcat ttltcgggta gtctcggttg gttgtttt aatcatatt ttgtttata  
 6781 aatatattt atttaccggg agtgggggga agtatagaga ttttatcgg gttaggggaag  
 6841 gaaattttgg gatgtgaaga cgaanaaga ggaagaagg aatatagaa ggaggaggtt  
 6901 tttagaaga ggaggtatg gtggggcga ttltggagg gaagtgaagg gttacgtta  
 6961 cgaatttt ttgtgttg tagttttgg ttgtttat ttaattagg cggctgcac  
 7021 gagagattat cgttgcgagg cgttgggttg ttgtatttc gaattttt ttltcggct  
 7081 tagattttt taagtccggg ttlttcggtt ttgggtttt ttgtttta tctgtcgggt  
 7141 cgttcgagg ttgggttta tctgttgggt tgcggcggtta cgttgttg ttggagagg  
 7201 cgttagggcg atgggggagg cggggtagt ttatttgc ttltcgggtg ttlttalc

7261 gaggttcggg gaagtttgaa gtagacnaa ggcgttgtt ttatttcgt ttggaagtta  
 7321 cgtcgcggag gagataaaa aggggtaggg ggggaaagt tatttagatt tttttttaa  
 7381 ttctgtggg tagcgataat tttttttaa agaaagacgg aggaagat cggggtagta  
 7441 aaaaacggcg tccgggttac ggtttttag cgtatattta cggcgggcg gcgggtagtt  
 7501 gtaaaagttaa gtgggtttt ggcgcgcgag tccgcgalt cgcggggag tgggtcgcg  
 7561 tgggggttag cgggtttacg tglagacgg ttagtagtc ggaagtggt ttgtagatt  
 7621 gtagtagggg ttacggttac gtaagtttc gggtagcgt gggcgggcg gtgagttgg  
 7681 acggttttc tgggtttt cggtagtag aggttttt ggcgcaggg ttltcgcgg  
 7741 aggggtttc ggggtcgcgt alaaattgt algagttcg gggcgcgic tgcgtcggg  
 7801 ggtttttc cgtcgcgc tcaatttgt tcaagtttc gtggtagcg gtcgtcgcg  
 7861 ttataggggt tgttagggg cgcgggggt tggggatgc ggcgcgcgg tacggtttt  
 7921 ttatcgcgc ggttagcggc gggagcgccg gtcgaaggt ttggttaa tatgtcgt  
 7981 ggaagggaaa atgtatttta ggtgtcgt cgtcgcgc ggtttgt ttattttgg  
 8041 cggtcgcgt cgtcgttt cgtcgttt tccgcgggt ttccggttt tgcgtcgt  
 8101 ttccggttg ttatagttag atatatatg ttattgat ttltcggc ggggtcgc  
 8161 tgcgcggt ttctgttt ttltcgcgc tctttttt ttlttcgg cgttgtagt  
 8221 attttcgt tctgtatat gttcgttt ttltgcgc tccgggttt ttctgttt  
 8281 ttatatagg ggcgcgggga gttggaagcg ttcgaggat cgaagatct ttgttcggg  
 8341 agtttttt ggttcgcgc gcgcgcgt ttccgtatt atatatagg ctcgcgcgc  
 8401 ggttcgttt tctcgttt tctcgttt ttltcgtc ctaggtttc gtttcgtt  
 8461 ttltcgcgc cgtttacgt tatttttt ttatttatt ttcttcgg ttlttttag  
 8521 ttltcgttt tgcgcgtagt cgtttttc ttltcgaa aattcgcgg ttltcgtc  
 8581 ttltttc ttlttcgg ttatttag tttttttc ggtttatt cgcgcgttt  
 8641 ttlttttt cgtttcgc gcgttttt ttgtttat agttaatt atcgtgtg  
 8701 ttlttcgtc gaaagcgc tagagatt ttittgta tgcgtatt taataataa  
 8761 tttatttta gttttcga ttgaaggt gttatagt agtatgt ttctgttt  
 8821 ttattttg ttttagcat ttatttt ttittttt aattattg tagatttt  
 8881 agtggcgga ggtttatt ggcgagtaa ttcggggag gncgtcgtt gagtctgt  
 8941 atttgatga gggcgaaag aggggtgt ttitttt ttattata ttlttcgg  
 9001 ttattgata ttatgtatc gttcgtagt cgttaggata aggggagga gagggcgcg  
 9061 tttggacgt agtggggaa gtatgtgtt gttgtgtt agtataaat aaatattga  
 9121 gatatttt attttttt aatttcgag ttittttg cgcgtttt gggagagata  
 9181 tatttttt ttattttc ggttagggag cgtatttc aatttttt attttatc  
 9241 atataatt ttittttt ttittaga tctgtgga atttttgt ttittttt  
 9301 cgttatata aatttttt ttittgag attaaaaaa aattgttt tctttata  
 9361 ttcggttc gtcgtcgt gtatatagc cgttttgt taaagttat aggtttgt  
 9421 attttaatt tgaagagg tgggtggga agttcgata aatttcgag gacgggtag  
 9481 agttatgta tttatttt ttccgagg ttttagtt ttgaagtt ttggggta  
 9541 ggggtttt agtttgt tctcgtagt attttgt ttgggtga ttattgt  
 9601 agttcgaat tagttagat ttatgtga agggattt ttlttcgga gttttatta  
 9661 ttattgt ttgaattgt tatagtaatt ttatatag cgtatcgt gttttata  
 9721 aacgttaaa attgtttta ggtataggt gattttta gatttttg gattttaa  
 9781 gaggtttta agttagggt attggagag ggaatttg alaaaaaa ttlttttag  
 9841 tattcgttt tttaataa aataaataa aataaataa aataaataa ttlttcggg  
 9901 ttittttta ataaagata ttatagtaa aataattaa taattgttt tttaggaat  
 9961 tatagttga attgattta gtaagaata ttittttg ttgttttg gcgattta  
 10021 tatttaatt tatatcga agtatatta gttttaga tcatlaaaa gaaagggt  
 10081 attagtagt agatagata ttgaatcgg ttittgatt ttatgtga ttattatg  
 10141 attttatta tatttttt ttatttt ttgaaggt tatttttt ttittttt  
 10201 ttaaaataa tattttata ttitttt tttaaatg agtatttt ataattg  
 10261 tttaataaa aaatgaagt aaaaaata attttat ataatgat ttitttgt  
 10321 ttatgtatt agtaataa ttatagaa gtaaatat ttattgt ttatgaat  
 10381 aataaatgt tagttatgg aagttagt ttacgatt taatatga alataatt  
 10441 atttttaa tatgagaaa aggatatt atttttt ttitttt ttgataaa  
 10501 ggaattaat tattattt aagaagaa aagataag ggaatttt gtagtatatt

10561 gttttatatt atgataaata taattttat ttgttatatt ttgttggtt taataaagg  
 10621 aaatattgta gtgatttat ttatagttta ttgttatatt aaatgggata ttltgaaaaa  
 10681 ttatattaat ttlttatgt attaaagta ttattaaata ttgtttagat ttlttttatt  
 10741 ttattaaata ttlttataa taltgatatt ttlttgatg aatgttaaat agaaaagtgtg  
 10801 gataaataata ttlttggtgt ttggggaga gtgaagtggg taatttggg gagtatttt  
 10861 tttaaattt tattattata atgtattatt attaattatt ttataaatt atatatatt  
 10921 tttatttttt ataaaattat ttataaata ttattatgtt taattttat aattttata  
 10981 gagttagattt taatttaaat aggaatttt ttaaaagttt taatttgta gtaagagatt  
 11041 gtttttgggt ttltatttat tgtaaaaatt ttgtgtgttt tatattgta aaattttagat  
 11101 ttagataata agaggttagg taggttttag taggagtaga gagaataagg agaatttaga  
 11161 atagagtttt gaggaagaaa gtgtattttt taltgggttaa agtatgtatt ataaaggaana  
 11221 ttggaatga acgtaaaaat tgttggtttt aaaaattatt tattttata attttttat  
 11281 ttagaanaa ttataaaga atttagatg gttaggttt agggagatg atgaattatt  
 11341 aaatgtatga gattatatt tagtttgga attattagg aatttttt ttgtttgtt  
 11401 ttgtttgtt ttlttgat agaattttat ttgtgttt aggttgaggt gtatggcgt  
 11461 aattttgtt taatttaatt ttgttttat ggttttagtg gttttttgt ttagttttt  
 11521 cgggtagtgt ggaattatagg ttlttataa taagttagt taattttgt atttttgta  
 11581 gagacgggtt ttattacgt ttgttaggtt ggttttaatt tttagtttt aagtgtatta  
 11641 ttgtttcgg ttlttaaaag tttaggatt ataggcgtga gttattatt ttgtttagga  
 11701 atttttttt ttatttaatt aagtaataag ttataagaat taatatatt ttgttatc  
 11761 ttgttggaat gttatggtt gaattgtgt gtactttta aattattatt ttgaatttt  
 11821 aatttataat gtatggttat taggaggttg tttagttaag ttatttgta gagttagtag  
 11881 ttlttttat tatgtggga tatagagatt aggtattatt tatgaataag ggaattaggt  
 11941 ttatttagat attaaattgt ttagtattac gttttgaat tttagttt ttagaattg  
 12001 gagaataaaa ttltgttg ttatagttt ttaggttata gtttttgtt atagtattt  
 12061 taataaata agatatggg ttatatagtt aaataatttt ttgttttgt taattttatt  
 12121 aggaagtta tagtttcga cgggagatta gatttttaat gaagttaaaa gagtggtaaa  
 12181 gaaggtatat aggtttata gagatagtat ataggagaga gggacaggtt ttatttaagt  
 12241 ggtgtttgt aggggtgtgt tttagtgga ggttttaaa acgcgtggga atttttaagt  
 12301 taggcagat aggttaggat attttaagtg gaagaataag gatgtttaga agcgttaagt  
 12361 ttgaanaag tatgttgt tttaggggaa ggggaagtaa ttgaatag aggaatttg  
 12421 ggtgttagg tagaggggtg gttatttat ttlttaggg ttaggttat ggaatagta  
 12481 agttaggta agaatattt taattttgt taggtatgat ggtttatgtt taataattta  
 12541 gtgttttgag aagttgaga gggaggatta ggaatttgag attagtttg ataatatagt  
 12601 aagattttgt ttlttaaaa aaagtaaaaa taagaataa tttaaattt taattttat  
 12661 ggaatgta aaataagggt taggggttt ttgagttagt agataaata tttaggaatt  
 12721 gattttttt ggtgaagggt gatttaatt ttlttaagag aatatttagt taggttagt  
 12781 ggtttatgt ttgaattta gtttttggg aggtcagggc ggggtgatta tttaggtta  
 12841 ggaatttgag attagtttg ttatatagt gaaattttgt ttlttataa aatttaaaaa  
 12901 aattagttag gtatgtggc ggttttgtt aattttagt attggaggt ttgagtagga  
 12961 gtattgttg aatttagag ggtgaggttg tagtgattta agatgtgtt attgtattt  
 13021 agtttgggag atagagtaag attttatta aaaaaaaaaa aaaaaaaaaa aaaaaagaga  
 13081 atattataa ttggcggat ttlttatgt ttattatta aggtttaga tta

=&gt;